Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + cytarabine + metformin
- Development stage
- Unknown
- Lead developer
- Hospital Municipal São José
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
VenCM is an experimental combination therapy comprising venetoclax, cytarabine, and metformin, currently under investigation for the treatment of relapsed-refractory and induction-ineligible acute myeloid leukemia (AML). This regimen, sponsored by Hospital Municipal São José, explores the repositioning of metformin—a biguanide typically used for type 2 diabetes—as an antineoplastic enhancer. Metformin inhibits complex I of the mitochondrial electron transport chain, which reduces oxidative phosphorylation (OXPHOS). This metabolic shift is hypothesized to synergize with venetoclax, a BCL-2 inhibitor, by overcoming mitochondrial-dependent resistance mechanisms in leukemia cells. Cytarabine is included as a standard cytotoxic antimetabolite that interferes with DNA synthesis, providing a multi-targeted approach to treating aggressive AML.
- Other names
- VenCM regimen
02
Targets
DNAND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on venetoclax + cytarabine + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + cytarabine + metformin.